Daesung Microbiological Labs대성미생물

Daesung Microbiological Labs is loss-making on a trailing basis, with its share price down about a quarter over the past year.

Daesung is a small Korean veterinary medicine maker with trailing six-month revenue of about ₩25.2B, a small operating loss of about ₩0.7B, and positive net income of about ₩0.8B. The shares closed at ₩5,520 on 28 October 2026, roughly half the 52-week high of ₩10,960, giving a market cap of about ₩21.0B.

What stands out

• Trailing operating margin is -2.6%, but net income is positive at ₩0.8B, so the profit line is being helped by items other than core operations.
• Full-year 2025 looked better, with revenue of ₩26.0B (up 9.2%) and operating income of ₩0.7B, but 2024 showed a large operating loss of ₩1.6B.
• Balance sheet carries borrowings of ₩16.4B against cash of ₩2.8B, and liabilities are 65.9% of equity.
• Valuation metrics are mixed: trailing P/E of 26.6 and P/B of 0.6, with a 1.4% dividend yield, while the trailing ROE is only 2.3%.
• Recent filings are mostly insider shareholding reports, plus an amended major sales contract filing on 30 September 2026. The data contains no news headlines.

What to watch

• The next filing from the company, the full-year 2026 results, since the trailing figures show a weak operating result.
• Whether the amended major sales contract filing points to a change in revenue or customer mix; the filing details are not in the data.
• Foreign ownership fell from 2.7% to 2.3% over 60 days, and the data does not explain the reason.